ETFChannel.com
ALNY Description — Alnylam Pharmaceuticals Inc

Alnylam Pharmaceuticals is a commercial-stage biopharmaceutical company developing therapeutics based on RNA interference. Co. has four RNAi-based medicines, ONPATTRO® (patisiran), GIVLAARI® (givosiran), OXLUMO™ (lumasiran) and Leqvio® (inclisiran). ONPATTRO is approved for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults. GIVLAARI is approved for the treatment of adults with acute hepatic porphyria. Co. has approval for OXLUMO for the treatment of hyperoxaluria type 1 (PH1) in all age groups. Leqvio (inclisiran) is being developed for the treatment of adults with hypercholesterolemia or mixed dyslipidemia.

Company Name: 
Alnylam Pharmaceuticals Inc
Website: 
www.alnylam.com
Sector: 
Drugs & Pharmaceuticals
Number of ETFs Holding ALNY: 
58
Total Market Value Held by ETFs: 
$2,857,520,011.69
Total Market Capitalization: 
$25,297,000,000
% of Market Cap. Held by ETFs: 
11.30%
 ETF   ALNY Weight   ALNY Amount 
 VTI   0.07%   $775,090,289         
 VO   0.47%   $599,192,776         
 VXF   0.45%   $354,545,475         
 VUG   0.16%   $213,643,828         
 VOT   0.98%   $175,544,830         
 IWP   0.82%   $90,652,800         
 IWF   0.15%   $83,810,456         
 VHT   0.45%   $83,151,712         
 XBI   1.08%   $72,933,631         
 IWR   0.29%   $72,930,178         
List of all 58 ETFs holding ALNY »
Quotes delayed 20 minutes

Email EnvelopeFree ALNY Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts

Buy (3.26 out of 4)
36th percentile
(ranked lower than approx. 64% of all stocks covered)

Analysts Forecast:
ALNY Price Target

Based on data provided by Zacks Investment Research via Quandl.com

ETFs Holding ALNY | Alnylam Pharmaceuticals Inc | ETF Channel | www.ETFChannel.com

Copyright © 2010 - 2022, All Rights Reserved Nothing in ETF Channel is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and ETF videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact ETF Channel; Meet Our Editorial Staff.